← Niagen Bioscience, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $26.8m |
$21.2m
-20.92%
|
$31.6m
+48.84%
|
$46.3m
+46.69%
|
$59.3m
+28.01%
|
$67.4m
+13.82%
|
$72.0m
+6.82%
|
$83.6m
+15.99%
|
$99.6m
+19.18%
|
$129.4m
+29.95%
|
$129.1m
-0.26%
|
|
| Cost of Goods and Services Sold | $14.9m |
$10.7m
-27.98%
|
$15.5m
+44.55%
|
$20.5m
+32.38%
|
$24.0m
+16.86%
|
$26.0m
+8.24%
|
$29.3m
+12.69%
|
$32.8m
+12.09%
|
$38.0m
+15.92%
|
$46.2m
+21.63%
|
$46.2m
-0.16%
|
|
| Gross Profit | $11.9m |
$10.5m
-12.11%
|
$16.1m
+53.24%
|
$25.8m
+60.50%
|
$35.3m
+36.89%
|
$41.5m
+17.62%
|
$42.8m
+3.15%
|
$50.8m
+18.65%
|
$61.6m
+21.28%
|
$83.2m
+35.08%
|
$82.9m
-0.32%
|
|
| Interest Income (Expense), Net | — | — | — | — | — | — | $3k |
$661k
+21933.33%
|
— | — | $1.9m | |
| Research and Development Expense | $2.5m | $4.0m | $5.5m | $4.4m | $3.7m | $3.8m | $4.8m | $5.0m | $6.0m | $6.3m | $6.5m | |
| Selling and Marketing Expense | $2.3m | $4.5m | $16.5m | $18.2m | $20.9m | $28.4m | $28.3m | $26.4m | $29.5m | $35.5m | $67.8m | |
| General and Administrative Expense | $9.4m | $17.6m | $27.1m | $34.3m | $30.4m | $36.4m | $28.3m | $25.0m | $18.4m | $27.1m | $28.8m | |
| Amortization of Intangible Assets | $88k | $206k | $235k | $246k | $243k | $225k | $186k | $158k | $151k | $173k | — | |
| Operating Lease, Expense | — | — | — | $663k | $501k | $1.1m | $1.3m | $1.2m | $1.3m | $1.3m | — | |
| Operating Expenses | $14.2m | $26.9m | $49.2m | $57.1m | $55.1m | $68.6m | $61.4m | $56.4m | $53.9m | $66.9m | $74.3m | |
| Operating Income (Loss) | ($2.2m) |
($16.4m)
-629.35%
|
($33.2m)
-102.55%
|
($31.3m)
+5.64%
|
($19.9m)
+36.57%
|
($27.1m)
-36.36%
|
($18.6m)
+31.19%
|
($5.6m)
+69.94%
|
$7.7m
+237.99%
|
$16.3m
+110.70%
|
$8.6m
-47.08%
|
|
| Interest Expense | $372k | $153k | $79k | $847k | $71k | $55k | — | — | — | — | — | |
| Gain (Loss) Related to Litigation Settlement | — | ($746k) | ($746k) | — | — | — | — | — | — | $2.0m | — | |
| Other Expenses | — | $746k | $75k | $125k | $0 | — | — | — | — | — | — | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | — | $1.1m | $1.9m | $1.9m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $18.2m | $17.0m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($2.9m) | ($16.5m) | — | — | — | — | — | — | $8.9m | $18.2m | $17.0m | |
| Income Tax Expense (Benefit) | $0 | $0 | — | — | — | — | — | — | $305k | $810k | $1.0m | |
| Net Income (Loss) Attributable to Parent | ($2.9m) |
($11.4m)
-288.56%
|
($33.3m)
-192.82%
|
($32.1m)
+3.51%
|
($19.9m)
+38.02%
|
($27.1m)
-36.15%
|
($16.5m)
+39.03%
|
($4.9m)
+70.15%
|
$8.6m
+273.15%
|
$17.4m
+103.30%
|
$16.0m
-8.00%
|
|
| Earnings Per Share, Basic | — | — | — | — | — | ($0.40) | ($0.24) | ($0.07) | $0.11 | $0.22 | $0.20 | |
| Earnings Per Share, Diluted | ($0.03) | ($0.26) | ($0.61) | ($0.56) | ($0.33) | ($0.40) | ($0.24) | ($0.07) | $0.11 | $0.20 | $0.19 | |
| Weighted Average Number of Shares Outstanding, Basic | 37.3m | — | — | — | — | 67.2m | 69.7m | 75.0m | 75.9m | 79.2m | 79.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 67.2m | 69.7m | 75.0m | 78.1m | 85.4m | 84.7m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | $0 | — | — | — | — | — | — | — | — | — | — | |
| Selling Expense | — | — | — | — | — | — | — | — | $9.8m | $11.3m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | $1.3m | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | ($16.5m) | ($33.3m) | — | — | — | $0 | $0 | $0 | $0 | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | $5.2m | $0 | — | — | — | $0 | $0 | $0 | $0 | — |